Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4934264 | 0.84 | MAPT (0.59) | SMN1; SMN2MAPTALDH1A1LMNAHTT | |
| SCHEMBL4925541 | 0.84 | CNR2 (0.58) | KDM4ETDP1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL1431678 | 0.83 | KEAP1 (0.49) | KDM4ESMN1; SMN2MAPTALDH1A1CNR1 | |
| SCHEMBL1431911 | 0.83 | PPARA (0.41) | KDM4ESMN1; SMN2MAPTALDH1A1CNR1 | |
| SCHEMBL1432255 | 0.83 | CYP1A2 (0.43) | KDM4EKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4927251 | 0.83 | PPARA (0.41) | KDM4ESMN1; SMN2MAPTALDH1A1CNR1 | |
| SCHEMBL4934207 | 0.83 | CYP1A2 (0.43) | KDM4EKMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4929226 | 0.83 | ALDH1A1 (0.48) | KDM4ETDP1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4932426 | 0.83 | PPARA (0.41) | KDM4ESMN1; SMN2MAPTALDH1A1CNR1 | |
| SCHEMBL1431859 | 0.83 | SMN1; SMN2 (0.53) | KMT2ASMN1; SMN2LMNACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | KDM4E 2084/4885TDP1 4304/4885KMT2A 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.